Robert Harrington to Oligonucleotides
This is a "connection" page, showing publications Robert Harrington has written about Oligonucleotides.
Connection Strength
0.475
-
Vein graft preservation solutions, patency, and outcomes after coronary artery bypass graft surgery: follow-up from the PREVENT IV randomized clinical trial. JAMA Surg. 2014 Aug; 149(8):798-805.
Score: 0.117
-
Edifoligide and long-term outcomes after coronary artery bypass grafting: PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) 5-year results. Am Heart J. 2012 Sep; 164(3):379-386.e1.
Score: 0.103
-
Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease. Circulation. 2008 Jun 03; 117(22):2865-74.
Score: 0.076
-
Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. JAMA. 2005 Nov 16; 294(19):2446-54.
Score: 0.064
-
The potential of aptamers as anticoagulants. Trends Cardiovasc Med. 2005 Jan; 15(1):41-5.
Score: 0.060
-
First clinical application of an actively reversible direct factor IXa inhibitor as an anticoagulation strategy in patients undergoing percutaneous coronary intervention. Circulation. 2010 Aug 10; 122(6):614-22.
Score: 0.022
-
First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity. Circulation. 2006 Dec 05; 114(23):2490-7.
Score: 0.017
-
The PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) trial: study rationale, design, and baseline patient characteristics. Am Heart J. 2005 Oct; 150(4):643-9.
Score: 0.016